{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Postbaseline Shift From Grade 0 to Grade 4 Low Potassium"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Postbaseline Shift From Grade 0 to Grade 3 AST"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Postbaseline Shift From Grade 0 to Grade 3 Bilirubin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Postbaseline Shift From Grade 0 to Grade 3 Serum GGT"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Postbaseline Shift From Grade 0 to Grade 3 High Glucose (Hyperglycemia),"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Postbaseline Shift From Grade 0 to Grade 3 Low Potassuium"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Postbaseline Serum Total Bilirubin >=2 ULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Postbaseline Shift From CTCAE Grade 0 to Grade 4 Low Neutrophil Count"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Postbaseline Shift From CTCAE Grade 0 to Grade 4 Low Leukocyte Count"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Postbaseline Shift From CTCAE Grade 0 to Grade 4 Low Platelet Count"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Postbaseline Shift From CTCAE Grade 0 to Grade 3 Low Leukocyte Count"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Postbaseline Shift From CTCAE Grade 0 to Grade 3 Low Neutrophil Count"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Postbaseline Shift From CTCAE Grade 0 to Grade 3 Low Platelet Count"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Postbaseline Shift From CTCAE Grade 0 to Grade 3 Low Hemoglobin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Postbaseline Shift From CTCAE Grade 1 to Grade 3 Low Hemoglobin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Postbaseline Shift From CTCAE Grade 1 to Grade 3 Low Leucocyte Count"}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"Laboratory parameters like Potassium, Aspartate Aminotransferase (AST), Bilirubin, Serum Gamma-glutamyl Transferase (GGT), High Glucose (Hyperglycemia), Neutrophils, Leukocytes, Platelets, and Hemoglobin were assessed.\n\nIntensity of changes in laboratory parameters were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.","groups":[{"description":"Participants received brentuximab vedotin 1.8 mg/kg, IV infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\\^2 and doxorubicin 50 mg/m\\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until PD, unacceptable toxicity, whichever occurred first.","id":"OG000","title":"Brentuximab Vedotin + CHP"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The FAS consisted of all enrolled participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 7 months","title":"Number of Participants With Abnormal Changes From Baseline in Laboratory Measurements","type":"PRIMARY","unitOfMeasure":"Participants"}